Addiction
-
Randomized Controlled Trial Multicenter Study
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
To describe drug use and safety with intramuscular injectable extended-release naltrexone (XR-NTX) in opioid dependence during a 1-year open-label extension phase. ⋯ During a 1-year open-label extension phase of injectable XR-NTX for the prevention of relapse in opioid dependence, 62.3% of patients completed the phase and 50.9% were abstinent from opioids. No new safety concerns were evident.